News
All the latest news from Quadratech Diagnostics. If you would like to receive updates via our newsletter then please sign up here.
5D Protein Stabilizer
For improved protein activity, shelf life, stability, cell attachment and more. Manufactured by 5-Diagnostics.
Forthcoming Meeting: Microparticles: Biomarkers of Disease?
Quadratech is sponsoring a Microparticles Meeting at the University of Leicester Tuesday 21st May 2013 A series of presentations by leading microparticles researchers from the UK and Amsterdam Medical Centre
Article of Interest (Epigenetics): Histone H4, Thrombosis & Inflammation
Molecular Circuits in Thrombosis and Inflammation. Esmon CT, 2013, Throm Haemost 109 (3):416-420 "In addition to the direct prothrombotic activity of histone-DNA complexes, the complexes trigger activation of the toll-like receptors 2, 4 and 9 thereby increasing inflammatory cytokine formation and fostering thrombotic responses through the mechanisms mentioned previously."
Article of Interest (Coagulation): Effect of Oral Contraceptive on protein S and TFPI
The effect of different hormonal contraceptives on plasma levels of free protein S and free TFPI. Raps M et al, 2013, Throm Haemost 109(4):[ahead of print] "The effect of oral contraceptives on TFPI and PS is a possible explanation for the increased risk of venous thrombosis associated with oral contraceptives"
Article of Interest (Coagulation):Factor Concentrates
The early use of fibrinogen, prothrombin complex concentrate, and recombinant-activated factor VIIa in massive bleeding.
Article of Interest:Vascular Biology
Early Vascular Alterations in SLE and RA Patients—A Step towards Understanding the Associated Cardiovascular Risk. Jose M et al, PLOS ONE www.plosone.org 1 September 2012 Volume 7 Issue 9
Is There a Difference in Anticoagulation Stability Between Domiciliary-Based and Hospital-Based Patients?
A study of patients in three different monitoring settings showed domiciliary-based patients had the poorest anticoagulation control.
Article of Interest (Coagulation) -The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors.
What is already known about this subject: A number of pharmacokinetics studies have focused on S-warfarin. These have shown that demographic factors, such as bodyweight, genetic factors, such as CYP2C9 genotype, and interacting medicines, particularly amiodarone, contribute to the interindividual estimates of clearance. What this study adds: This study not only reinforces what has previously been learned about S-warfarin, but also provides an insight into the pharmacokinetics of R-warfarin.
Article of Interest (Coagulation) – Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants.
What is already known about this subject: Observation from clinical studies have demonstrated that: • CYP2C19 genotype does not have a clinically relevant effect on active metabolite concentrations or platelet inhibition in prasugrel-treated subjects • Variability of response to clopidogrel active metabolite and reduced platelet inhibition lead to increased adverse cardiovascular events in patients with acute coronary syndromes
Largest Selection of β-Amyloid and Related Peptides from Bio-Synthesis Inc.
Amyloid Precursor Protein (APP) is a transmembrane protein that is predominantly expressed in the brain. Mutations and subsequent cleavages of APP by β-secretase, ϒ-secretase and caspases generated amyloid beta peptides, which have been implicated in the pathogenesis of Alzheimer's disease. Proteolytic action of β-secretase and ϒ-secretase generates amyloid β peptides of 40 or 42 residues. These peptides are susceptible to aggregate and lead to formation of amyloid plaques that characterizes Alzheimer disease.
Selected Publications Citing 21st Century Biochemicals Custom Antibodies
Quadratech supplies high quality Epigenetic Peptides and Antibodies, Custom Peptides, Custom Antibodies, Antibodies to Selected Targets and Bioactive Peptides. These have been successfully used in many research laboratories.
Bio-Synthesis Inc. Introduces “BNA-NC”
Bio-Synthesis Inc. Introduces "BNA-NC" - A Third Generation Multi Functional Bridged Nucleic Acid Bio-Synthesis is proud to announce that it has acquired a license from BNA Inc. of Osaka, Japan for the manufacturing and distribution of BNA-NC, a third generation of BNA oligonucleotides. This agreement is valid worldwide and is meant for research use only at this time (Patents JP: 4731324(2011.4.28), USP: 7427672(2008.9.23), EP: 1551905(2012.4.25)).
